Annette Matthies
Corporate Officer/Principal bij Elicio Therapeutics, Inc. (Old)
Profiel
Annette M.
Matthies is currently the Chief Business Officer at Elicio Therapeutics, Inc. She previously worked as the Senior Director-Corporate Development at Receptos LLC from 2012 to 2015, Associate Director-New Product Planning at Abbott Laboratories, Inc. from 2010 to 2011, Head-Business Development & Market Research at Biogen, Inc. and Abbott Biotherapeutics Corp.
She also served as the Vice President-Corporate Development at eFFECTOR Therapeutics Operations, Inc. from 2016 to 2019.
Dr. Matthies has an undergraduate degree from Augustana College (Illinois) and a doctorate from Loyola University New Orleans.
Actieve functies van Annette Matthies
| Bedrijven | Functie | Begin |
|---|---|---|
Elicio Therapeutics, Inc. (Old)
 Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01-01-2021 |
Eerdere bekende functies van Annette Matthies
| Bedrijven | Functie | Einde |
|---|---|---|
| ELICIO THERAPEUTICS, INC. | Corporate Officer/Principal | 05-10-2023 |
eFFECTOR Therapeutics Operations, Inc.
 eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 02-01-2019 |
| RECEPTOS INC | Corporate Officer/Principal | 01-01-2015 |
Abbott Laboratories, Inc.
 Abbott Laboratories, Inc. Medical SpecialtiesHealth Technology Part of Abbott Laboratories, Inc., the company manufactures and wholesales diagnostic and pharmaceutical products as well as medical devices. The company is based in Chicago, IL. | Corporate Officer/Principal | 01-01-2011 |
| BIOGEN INC. | Corporate Officer/Principal | - |
Opleiding van Annette Matthies
| Augustana College (Illinois) | Undergraduate Degree |
| Loyola University New Orleans | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BIOGEN INC. | Health Technology |
| ELICIO THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Health Technology |
eFFECTOR Therapeutics Operations, Inc.
eFFECTOR Therapeutics Operations, Inc. Miscellaneous Commercial ServicesCommercial Services eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA. | Commercial Services |
Receptos LLC
 Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
Abbott Laboratories, Inc.
Abbott Laboratories, Inc. Medical SpecialtiesHealth Technology Part of Abbott Laboratories, Inc., the company manufactures and wholesales diagnostic and pharmaceutical products as well as medical devices. The company is based in Chicago, IL. | Health Technology |
Abbott Biotherapeutics Corp.
 Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Health Technology |
